Docs say Merck has best reputation
More than 13,000 physicians in 24 specialty groups recognized Merck as having the best overall reputation among pharmaceutical companies, according to a new report from IMS America, Somerset, NJ, and the Plymouth Group, Plymouth Meeting, PA.
More than 13,000 physicians in 24 specialty groups recognized Merck as having the best overall reputation among pharmaceutical companies, according to a new report from IMS America, Somerset, NJ, and the Plymouth Group, Plymouth Meeting, PA.
Merck was also named best overall company by doctors in nine individual specialties, including general and family practitioners, internists, general surgeons, infectious disease specialists, cardiologists, nephrologists, orthopedic surgeons, rheumatologists and urologists.
The recent launches of three major products - Cozaar, Fosamax and Proscar - were influential in securing Merck its win. The growing popularity of its drugs Zocor and Vasotec may have factored in the report's results as well.
Companies were judged according to four attributes: research and development efforts, product line, educational programs and value-added services.
Physicians also evaluated the performances of pharmaceutical sales forces by their knowledge, professional style, service and sample availability.
The combined response from the 24: Astra-Merck's sales force took top honors among all physicians in every one of the four evaluation categories. It was also named by physicians as one of the two most familiar sales forces. PR
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Asembia 2025: Therapy Advancements Highlight Growing Cost and Access Concerns
April 30th 2025Fran Gregory, VP, emerging therapies, Cardinal Health, discusses the evolving cell and gene therapy landscape, highlighting pipeline growth, cost challenges, and emerging therapeutic areas beyond oncology and hematology.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
